Skip to content
Download PDF

Basic Biology of the Cardiovascular System

Chapter 244 | Part 6: Disorders of the Cardiovascular System · Part 6 – Cardiovascular Disorders · Chapter 244

Key Clinical Points

  1. Pitfalls in cardiovascular medicine include: 1) Noncardiologists failing to recognize cardiac manifestations of systemic illnesses (e.g., mitral stenosis/stroke, pulmonary hypertension/scleroderma). 2) Cardiologists failing to recognize underlying systemic disorders in heart disease (e.g., hyperthyroidism in AFib, Lyme disease in AV block). 3) Overreliance on invasive tests (catheterization) without a thorough clinical history.
  2. Prevention principles: 1) In the absence of disease, inform patients and avoid repeated examinations to prevent unnecessary concern. 2) For patients with risk factors but no disease, implement lifestyle changes (weight, activity, smoking cessation) and treat hypertension, lipids, and diabetes. 3) Asymptomatic/mildly symptomatic patients with severe valvular anatomy require evaluation every 6–12 months. 4) Revascularization should be limited to cases that improve natural history (e.g., ACS or multivessel CAD with LV dysfunction).
  3. Embryology: The heart forms from lateral splanchnic mesoderm; the first heart field forms the linear heart tube, while the second heart field adds myocardium to inflow/outflow poles. Neural crest cells orchestrate aortic arch remodeling and are sensitive to Vitamin A and folic acid.
  4. Endothelial Function: Healthy endothelium maintains balance of vasodilation/constriction, is antithrombotic/antifibrinolytic, anti-inflammatory, antiproliferative, antioxidant, and maintains selective permeability. Dysfunction leads to prothrombotic, proinflammatory, proproliferant, and prooxidant states.
  5. Vascular Smooth Muscle Contraction: Driven by increased cytoplasmic calcium via transmembrane influx (L-type channels) and release from the sarcoplasmic reticulum (RyR2), activating myosin light chain kinase (MLCK). Relaxation involves myosin light chain phosphatase (MLCP).
  6. Cardiac Contractility: Determined by preload (muscle length/EDV), afterload (resistance), and contractility (shortening velocity). Starling's law states force is optimal at specific sarcomere lengths (~2.2 μm).
  7. Calcium Handling: Action potential triggers Ca2+ influx, causing Ca2+-induced Ca2+ release from the SR. β-adrenergic stimulation increases Ca2+ influx and SR uptake via phospholamban (PL) phosphorylation, enhancing both contraction (inotropic) and relaxation (lusitropic).

DEFINITION & OVERVIEW

• Scope: The chapter covers developmental biology, vascular cell biology, and cardiac physiology. • Core Topics: ◦ Embryogenesis of the heart and origin of vascular cells. ◦ Ultrastructure of blood vessels and cardiomyocytes. ◦ Mechanisms of vascular tone and cardiac contraction. ◦ Control of cardiac performance.

PITFALLS IN CARDIOVASCULAR MEDICINE

• Pitfall 1: Failure to Recognize Cardiac Manifestations of Systemic Illnesses ◦ Noncardiologists may fail to identify: - Mitral stenosis, patent foramen ovale, or transient atrial arrhythmia in patients with stroke. - Pulmonary hypertension and cor pulmonale in patients with scleroderma or Raynaud's syndrome. - The necessity of a thorough cardiovascular exam to assess the severity of involvement in noncardiac disorders. • Pitfall 2: Failure to Recognize Systemic Disorders in Heart Disease ◦ Cardiologists may fail to identify: - Hyperthyroidism in elderly patients with atrial fibrillation and unexplained heart failure. - Lyme disease in patients with fluctuating atrioventricular block. - Pericardial effusion as an early clue for tuberculosis or neoplasm. • Pitfall 3: Overreliance on Invasive Techniques ◦ Risk of overutilization of coronary arteriography without a careful history. - Arteriograms show obstruction but do not always determine if symptoms are due to atherosclerosis or if revascularization is indicated. - Invasive tests carry risk, discomfort, and resource strain; they should only be performed if results are expected to modify management.

DISEASE PREVENTION AND MANAGEMENT

• Prevention Principles: ◦ Risk assessment → Lifestyle modifications (weight, activity, smoking) → Treatment of risk factors (hypertension, lipids, diabetes). • Management of Valvular Heart Disease: ◦ Assessment: Patients with anatomically severe disease should be evaluated every 6–12 months via clinical and noninvasive exams. - Early signs of ventricular dysfunction may indicate the need for surgery before irreversible damage or high surgical risk occurs. • Revascularization Criteria: ◦ Decision based on whether revascularization improves natural history. - Indications: Acute coronary syndrome (ACS) or multivessel CAD with left ventricular dysfunction.

DEVELOPMENTAL BIOLOGY OF THE CARDIOVASCULAR SYSTEM

• Heart Tube Formation and Looping: ◦ Origin: Lateral splanchnic mesoderm. ◦ Structure: Single layer of endocardium and a single layer of spontaneously beating cardiomyocytes. ◦ Growth: Chamber specification, asymmetric looping, and longitudinal/concentric growth. ◦ Additional Cells: Pharyngeal mesoderm (expressing Islet-1) contributes to the right atrium and right ventricle. • Origin of Vascular Cells: ◦ Upper-body arterial smooth muscle: Neural crest. ◦ Lower-body arterial smooth muscle: Mesoderm. ◦ Endothelial progenitors: Mesoderm. ◦ Descending aorta: Lateral plate mesoderm. - Note: Neural crest cells are sensitive to Vitamin A and folic acid; deficiencies lead to aortic arch defects. • Cardiac Conduction System Development: ◦ Differentiation from cardiomyocyte precursors. ◦ Slow-conducting (proximal): SA node, AV node. ◦ Fast-conducting (distal): His bundle, bundle branches, Purkinje fibers.

THE BLOOD VESSEL

• Vascular Ultrastructure: ◦ Capillaries: Endothelial tube in contact with a discontinuous population of pericytes. ◦ Veins: Thin media and thicker adventitias. ◦ Small muscular artery: Prominent tunica media. ◦ Large muscular artery: Prominent media with smooth-muscle cells in complex extracellular matrix. ◦ Large elastic artery: Cylindrical layers of elastic tissue alternating with concentric rings of smooth-muscle cells; includes vasa vasorum for nutrient supply. • Endothelial Cell Biology: ◦ Function: Balance of vasodilation/constriction, antithrombotic, anti-inflammatory, antiproliferative, antioxidant, and barrier function. ◦ Dysfunction: Leads to prothrombotic, proinflammatory, proproliferant, and prooxidant states; impaired barrier function. - Table 1: Endothelial Functions in Health and Disease (Homeostatic vs. Dysfunctional).

CELLULAR BASIS OF CARDIAC CONTRACTION

• Cardiac Activation: ◦ Mechanism: Sliding filament model; ATP hydrolysis. ◦ Calcium Role: Ca2+ binds to troponin C → exposes actin sites → cross-bridge cycling. ◦ Relaxation: Requires Ca2+ reuptake into SR via SERCA (ATP-dependent) and extrusion via Na+/Ca2+ exchanger. • Control of Cardiac Performance: ◦ Preload: Length of the muscle at the onset of contraction (end-diastolic volume/pressure). ◦ Afterload: Tension that the muscle must develop during contraction (arterial resistance). ◦ Contractility: Extent and velocity of shortening at any given preload and afterload. - Starling's Law: Force is optimal at specific sarcomere lengths (~2.2 μm). • β-adrenergic Stimulation: ◦ Inotropy: Increased rate of contraction and peak force via cAMP/PKA activation. ◦ Lusitropy: Enhanced relaxation via phospholamban (PL) phosphorylation, facilitating faster Ca2+ uptake into the SR.

FLOWCHARTS & ALGORITHMS

• Assessment of Endothelial Function (Flowchart 1): 1. Baseline: Measure arterial diameter and flow under normal conditions. 2. Occlusion: Apply blood pressure cuff to stop blood flow. 3. Release/Hyperemia: Deflate cuff to induce hyperemic state. 4. Comparison: - Significant increase in diameter (e.g., 4.0 mm → 4.8 mm) and flow volume → Normal Endothelial Function. - Minimal or absent increase in diameter/flow → Endothelial Dysfunction. • Mechanisms of Diastolic Dysfunction (Flowchart 2): 1. Identify primary mechanical driver: - Increased Chamber Stiffness: Results in higher pressures for any given volume (steeper pressure-volume relationship, increased dP/dV). - Chamber Dilation: Results in larger volumes at lower pressures (increased end-diastolic volume). 2. Clinical Outcome: - Higher pressures lead to impaired filling; higher volumes may lead to pulmonary edema.

KEY PEARLS & HIGH-YIELD POINTS

• Table 2: Determinants of Stroke Volume - Preload: Blood volume, distribution (body position, pressure), atrial contraction. - Afterload: Systemic vascular resistance, elasticity of arterial tree, ventricular wall tension. - Contractility: Intramyocardial [Ca2+], adrenergic activity, circulating catecholamines, inotropic agents, and myocardial health (less fibrosis/hypertrophy). • Pressure-Volume Loop Dynamics: - Afterload \uparrow → Stroke volume falls (movement along the ESPVR curve). - Preload \uparrow → Stroke volume rises. - Contractility \uparrow → ESPVR shifts left (steeper slope); Contractility \downarrow → ESPVR shifts right (flatter slope). • Vascular Cell Origins: - Neural crest: Upper-body arterial smooth muscle. - Mesoderm: Lower-body arterial smooth muscle, endothelial progenitors, and lateral plate mesoderm for descending aorta.

Reference Tables

TABLE 244-1 Endothelial Functions in Health and Disease

Harrison's 22e, p.1845

  • DYSFUNCTIONAL PROPERTIES
  • Impaired dilation, vasoconstriction

TABLE 244-2 Determinants of Stroke Volume I. Ventricular Preload

Harrison's 22e, p.1852

  • I. Ventricular Preload
    A. Blood volume
    B. Distribution of blood volume
    1. Body position
    2. Intrathoracic pressure
    3. Intrapericardial pressure
    4. Venous tone
    5. Pumping action of skeletal muscles
    C. Atrial contraction
    II. Ventricular Afterload
    A. Systemic vascular resistance
    B. Elasticity of arterial tree
    C. Arterial blood volume
    D. Ventricular wall tension
    1. Ventricular radius
    2. Ventricular wall thickness
    III. Myocardial Contractilitya
    A. Intramyocardial [Ca2+] ↑↓
    B. Cardiac adrenergic nerve activity ↑↓b
    C. Circulating catecholamines ↑↓b
    D. Cardiac rate ↑↓b
    E. Exogenous inotropic agents ↑
    F. Myocardial ischemia ↓
    G. Myocardial cell death (necrosis, apoptosis, autophagy) ↓
    H. Alterations of sarcomeric and cytoskeletal proteins ↓
    1. Genetic
    2. Hemodynamic overload
    I. Myocardial fibrosis ↓
    J. Chronic overexpression of neurohormones ↓
    K. Ventricular remodeling ↓
    L. Chronic and/or excessive myocardial hypertrophy ↓
  • Preload
  • Contractility
  • Maximal activity 2 C Normal-exercise
    1
    Normal-rest
    Contractile state of myocardium
    Walking 3
  • B
    Exercise
    3′
    Rest D Heart failure
  • A
    E Fatal myocardial
    4
    depression